Time to strategy failure and treatment beyond progression in pretreated metastatic renal cell carcinoma patients receiving nivolumab: post-hoc analysis of the Meet-URO 15 study
Time to strategy failure and treatment beyond progression in pretreated metastatic renal cell carcinoma patients receiving nivolumab: post-hoc analysis of the Meet-URO 15 study
Bimbatti, D.;Milella, M.;Prati, V.;Caffo, O.;Spada, M.;
2024-01-01
Abstract
Time to strategy failure and treatment beyond progression in pretreated metastatic renal cell carcinoma patients receiving nivolumab: post-hoc analysis of the Meet-URO 15 study
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
fonc-14-1307635.pdf
accesso aperto
Licenza:
Dominio pubblico
Dimensione
694.19 kB
Formato
Adobe PDF
|
694.19 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
